Vaccitech plc

General Information
We co-invented a COVID-19 vaccine candidate with the University of Oxford, which we assigned to Oxford University Innovation, or OUI, to facilitate the license of those rights by OUI to AstraZeneca UK Limited, or AstraZeneca. This vaccine is now known as COVID-19 Vaccine AstraZeneca, which we refer to as AZD1222. AstraZeneca has exclusive worldwide rights to develop and commercialize AZD1222,” the prospectus says.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. 
We have a broad pipeline of clinical and preclinical therapeutic and prophylactic programs. Our therapeutic programs include VTP-300 to treat chronic hepatitis B infection (CHB); VTP-200 to treat human papilloma virus infection (HPV); VTP-850 to treat prostate cancer, and VTP-600 to treat non-small cell lung cancer (NSCLC). Our prophylactic programs include VTP-400 to prevent herpes zoster, or shingles, and VTP-500 to prevent Middle East respiratory syndrome, or MERS. 
(Note: Vaccitech priced its IPO on April 29, 2021, at $17 – the mid-point of its $16-to-$18 range – on 6.5 million shares, the same number of shares as in the prospectus – to raise $110.5 million.)
Employees: 48
Founded: 2016
Contact Information
Address Vaccitech plc The Schrödinger Building Heatley Road The Oxford Science Park Oxford OX4 4GE United Kingdom
Phone Number +44 (0) 1865 818 808
Web Address
View Prospectus: Vaccitech plc
Financial Information
Market Cap $579.02mil
Revenues $4.82 mil (last 12 months)
Net Income $-17.93 mil (last 12 months)
IPO Profile
Symbol VACC
Exchange NASDAQ
Shares (millions): 6.5
Price range $17.00 - $17.00
Est. $ Volume $110.5 mil
Manager / Joint Managers Morgan Stanley/ Jefferies/ Barclays/ William Blair
CO-Managers H.C. Wainwright & Co.
Expected To Trade: 4/30/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change